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Abstract
Rationale—India reports the largest number of multidrug-resistant tuberculosis cases in the 
world; yet, no longitudinal study has assessed factors related to treatment outcomes under 
programmatic conditions in the public sector.
Objectives—To describe demographic, clinical, and risk characteristics associated with 
treatment outcomes for all patients with multidrug-resistant tuberculosis registered in the Revised 
National Tuberculosis Control Programme, Kerala State, India from January 1, 2009 to June 30, 
2010.
Methods—Cox regression methods were used to calculate adjusted hazard ratios with 95% 
confidence intervals (CIs) to assess factors associated with an unsuccessful treatment outcome.
Measurements and Main Results—Of 179 patients with multidrug-resistant tuberculosis 
registered, 112 (63%) had successful treatment outcomes (77 bacteriologically cured, 35 treatment 
completed) and 67 (37%) had unsuccessful treatment outcomes (30 died, 26 defaulted, 9 failed 
treatment, 1 stopped treatment because of drug-related adverse events, and 1 developed 
extensively drug-resistant tuberculosis). The hazard for unsuccessful outcome was significantly 
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higher among patients who consumed alcohol during treatment (adjusted hazard ratio, 4.3; 95% 
CI, 1.1–17.6) than those who did not. Persons who consumed alcohol during treatment, on 
average, missed 18 more intensive-phase doses (95% CI, 13–22) than those who did not. Although 
many patients had diabetes (33%), were ever smokers (39%), or had low body mass index (47%), 
these factors were not associated with outcome.
Conclusion—Overall treatment success was greater than global and national averages; however, 
outcomes among patients consuming alcohol remained poor. Integration of care for multidrug-
resistant tuberculosis and alcoholism should be considered to improve treatment adherence and 
outcomes.
Keywords
multidrug-resistant tuberculosis treatment outcome; multidrug-resistant tuberculosis; alcohol; 
tuberculosis; India
In 2012, the estimated incidence of multidrug-resistant tuberculosis was 310,000 globally, of 
which 66,000 (21%) were in India (1–3). Multidrug-resistant tuberculosis, defined as 
tuberculosis caused by Mycobacterium tuberculosis resistant to at least both isoniazid and 
rifampicin, has become a major barrier to achieving tuberculosis control. Multidrug-resistant 
tuberculosis therapy is less effective, is associated with more adverse events, and is more 
costly to treat when compared with standard first-line therapy (2, 4, 5). Inadequate treatment 
of multidrug-resistant tuberculosis, poor adherence to short-course chemotherapy, poor 
clinical management practices, and underuse of diagnostic services has exacerbated the 
epidemiology, developing further resistance to second-line and even tertiary antituberculosis 
drugs, resulting in extensively and “totally” drug-resistant tuberculosis (3–10).
In India, the prevalence of multidrug-resistant tuberculosis is estimated to be 3% among new 
cases and 17% among previously treated cases (2). The Revised National Tuberculosis 
Control Program has established a program for the diagnosis, treatment, and management of 
multidrug-resistant tuberculosis using high-quality, second-line antituberculosis drugs at no 
cost to patients (3). Despite this accomplishment, only a small fraction (5%) of all 
multidrug-resistant tuberculosis cases in India were treated according to these standards in 
2011 (11). With the rapid and ambitious plan to scale up multidrug-resistant tuberculosis 
services by 2017 (12), understanding the effectiveness of this program is urgent. However, 
no longitudinal study has either assessed or described treatment outcomes of multidrug-
resistant tuberculosis cases in the public sector of India. Thus, we sought to investigate 
potential factors that might affect treatment outcomes using routinely collected 
programmatic data in India—a country with the most multidrug-resistant tuberculosis cases 
in the world (1, 11). Some of the results of these studies have been previously reported in the 
form of an abstract (13).
Methods
Study Population
We abstracted clinical records and tuberculosis program records and reports of all culture-
confirmed multidrug-resistant tuberculosis cases receiving treatment from the Revised 
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National Tuberculosis Control Programme in the state of Kerala from January 1, 2009 
through June 30, 2010. Kerala is India’s southernmost state, with a population of 
approximately 33 million people.
Diagnosis, Treatment, and Follow-Up
In Kerala, persons suspected of multidrug-resistant tuberculosis (previously treated 
tuberculosis cases, persons who failed tuberculosis treatment, persons with sputum-smear 
positive test results who had known exposure to multidrug-resistant tuberculosis) sought 
care at the Peripheral Health Institutions. All sputum specimens were collected and 
transported to the tuberculosis reference laboratories in Chennai and Trivandrum. Culture 
and drug susceptibility tests for first-line drugs (i.e., isoniazid, rifampicin, ethambutol, and 
streptomycin) were performed by conventional solid culture method using Lowenstein-
Jensen medium. Although all patients received drug susceptibility tests on the initial positive 
culture, repeat follow-up drug susceptibility tests are performed only for default patients 
who have completed initial 3 months of intensive-phase treatment and then return for 
treatment (3).
Diagnosed multidrug-resistant tuberculosis cases are then referred to tertiary care centers 
called Drug Resistant Tuberculosis Centres for initiation of treatment. Pretreatment clinical 
examinations are a prerequisite before the initiation of multidrug-resistant tuberculosis 
treatment. These examinations include chest radiograph; complete hemogram; liver, renal 
and thyroid function tests; HIV serology; screening for diabetes mellitus; calculation of 
body mass index; and pregnancy test for all women. All cases are then required to complete 
at least 7 days of inpatient treatment at Drug Resistant Tuberculosis Centres at the initiation 
of treatment (3). During this time, early-onset drug-related adverse events and drug 
intolerance are monitored and, if needed, dosage and/or drugs prescribed are modified. After 
1 week of treatment at Drug Resistant Tuberculosis Centres, patients are discharged to 
continue the treatment at their residence with daily supervised directly observed therapy by 
trained health care providers. All patients with multidrug-resistant tuberculosis were treated 
with a standardized, World Health Organization–recommended treatment regimen 
composed of an intensive phase for 6 months with kanamycin, levofloxacin, cycloserine, 
ethionamide, pyrazinamide, and ethambutol, and continuation phase of 18 months with 
levofloxacin, cycloserine, ethionamide, and ethambutol (3).
Routine follow-up clinic visits to monitor adverse drug-related events (e.g., nausea or 
vomiting, neuropathy, ototoxicity, psychosis, renal insufficiency, seizures, and suicidal 
ideation) occurred monthly throughout treatment and whenever indicated. The decision to 
stop treatment because of adverse drug-related events was based on the clinician’s 
discretion, and these events were not coded for severity. Bacteriological monitoring was 
done using sputum cultures at months 3, 4, 5, and 6 during the intensive phase. At the end of 
6 months of treatment, if the fourth-month culture remained positive, the intensive phase 
was extended for an additional 3 months. Additional sputum culture examinations continued 
every third month through month 24 (e.g., months 9, 12, 15, 18, 21, and 24). Patients who 
failed multidrug-resistant tuberculosis treatment underwent drug susceptibility tests using a 
modified proportion sensitivity method for liquid culture for second-line drugs like 
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ofloxacin and kanamycin at the Tuberculosis Research Centre, Chennai for a diagnosis of 
extensively drug-resistant tuberculosis.
Time to multidrug-resistant tuberculosis treatment initiation was calculated as the difference 
in number of days between sputum collection and multidrug-resistant tuberculosis treatment 
start date. Alcohol consumption and tobacco smoking were based on self-report and were 
documented in routine medical examinations and follow-up clinic visits. Patients self-
reporting a history of diabetes mellitus or those with fasting blood glucose greater than or 
equal to 126 mg/dl were defined as diabetic.
Treatment Outcome Definitions
Treatment outcomes were defined as successful or unsuccessful. Successful treatment 
outcomes were defined as cured (completed treatment with at least five consecutive negative 
culture results in the last 12–15 months) or completed (completed treatment as per national 
guidelines (3), but did not have all bacteriological results available). All other treatment 
outcomes were considered unsuccessful. This included treatment failure as determined by 
having two of five or the final three cultures positive, death from any cause during 
treatment, treatment interruptions for 2 or more consecutive months, transfer to another 
Drug Resistant Tuberculosis Centre and treatment outcome remained unknown; treatment 
having been stopped because of severe adverse drug reaction events; or the development of 
additional resistance and was subsequently prescribed a regimen for extensively drug-
resistant tuberculosis.
Statistical Analysis
Frequencies and proportions were calculated for all variables. Pearson’s Chi-square test and 
Fisher exact test (when appropriate) were used to compare differences in proportions 
between groups (i.e., successful vs. unsuccessful outcome). For continuous variables, we 
calculated medians, interquartile ranges, means, and standard deviations. To test for 
differences in means between groups, we used t test or Kruskal-Wallis test as applicable. We 
calculated time-to-event (i.e., outcome) in months using the difference between the 
treatment start date and treatment end date. Deaths included death of any cause during 
treatment; otherwise, individuals were censored at the treatment end date, or date of 
outcome, as outlined above. We used Kaplan-Meier curves to compare unadjusted time-to-
event ratios among tuberculosis cases for both successful and unsuccessful treatment 
outcomes. Differences across strata were examined using the log-rank test. A Cox 
proportional hazards model with a stepwise backward elimination approach was used to 
assess the effect of select clinical and demographic variables on time-to-event during 
treatment. Hazard ratios (HRs) were used as the measure of association with 95% 
confidence intervals (CIs). The proportionality of risks in the Cox model was verified using 
a Schoenfeld residuals plot. Relative risk and corresponding 95% CI were calculated to 
measure the association between consuming alcohol during treatment and missing more than 
seven doses during the intensive phase. All statistical tests were considered to be significant 
at an a less than 0.05.
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Ethics Considerations
The study protocol was reviewed and approved by the Ethics Advisory Group of the 
International Union Against tuberculosis and Lung disease (Paris, France) and the 
Institutional Ethics Committee of the National Tuberculosis Institute, Bangalore, India. 
These data were collected and analyzed as part of routine public health activities, so no 
informed consent was required. All data were safeguarded to protect patient confidentiality 
and no individual patient identifiers were retained. Participation of the United States Centers 
for Disease Control and Prevention in this project did not meet the definition of engagement 
in human subjects research because the U.S. Centers for Disease Control and Prevention 
investigators did not interact with study subjects or have access to patient identifiable data; 
thus, a separate institutional review board approval was not required.
Results
During January 1, 2009 through June 30, 2010, 1,207 persons in Kerala sought care for 
suspected multidrug-resistant tuberculosis. Among these, 202 (16.7%) had M. tuberculosis 
isolates that were resistant to at least isoniazid and rifampin. Nearly 90% (n = 179) of the 
multidrug-resistant tuberculosis patients initiated treatment during the study period; 139 
(77.7%) were men and 40 (22.3%) were women. The median age was 45 years (interquartile 
range, 35–53 yr). The majority of patients (68.7%) reported a daily income below the 
international poverty line (United States $1.25).
At the time of pretreatment clinical assessment, 60 (33.5%) patients had diabetes, 5 (2.8%) 
had evidence of cardiovascular disease, 2 (1.1%) had hypothyroidism, and 1 (0.6%) was 
HIV seropositive. Nearly one-half of the patients (n = 85) had a body mass index less than 
18.5 before the start of multidrug-resistant tuberculosis treatment. Nearly all (98.9%) were 
previously treated with first-line antituberculosis drugs (Table 1).
Of 179 patients with multidrug-resistant tuberculosis treatment outcome, 77 (43.0%) were 
classified as cured per bacteriology, 35 (19.6%) completed treatment, 30 (16.8%) died, 26 
(14.5%) defaulted, 9 (5%) failed treatment, 1 (0.6%) stopped treatment because of a severe 
adverse drug-related event, and 1 (0.6%) developed extensively drug-resistant tuberculosis. 
There was no meaningful or statistically significant difference between the time to 
multidrug-resistant tuberculosis treatment initiation between those with successful outcomes 
and unsuccessful outcomes (P = 0.67); however, on average, it took 145 days to start 
multidrug-resistant tuberculosis treatment (SD, ±58 days).
Sex, age group, living below the poverty line, self-reported alcohol consumption before 
treatment, self-reported smoking before treatment, smoking during treatment, HIV 
seropositivity, diabetes mellitus, pulmonary cavities, low body mass index, and the number 
of prior tuberculosis episodes were all not associated with outcome based on crude HR 
calculations (Table 1).
Treatment-related adverse events were identified in 71 (39.6%) patients during the course of 
the treatment, but these events were not associated with outcome. Of note, 29 (16.2%) were 
psychiatric events, including one suicidal ideation. Gastrointestinal upset (13.4%), arthralgia 
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(10.1%), ototoxicity, (6.1%), nephrotoxicity (5.0%), neuropathy (2.8%), and jaundice 
(1.1%) were also identified during treatment. Overall, those requiring hospitalization during 
treatment had higher hazard for unsuccessful outcome (HR, 1.7; 95% CI, 1.1–2.7) than those 
not hospitalized. Those consuming alcohol during treatment (HR, 4.9; 95% CI, 1.2–20.3) 
(Table 1, Figure 1) had higher hazard for poor outcome than those who did not. After 
adjusting for hospitalization during treatment, persons who consumed alcohol during 
treatment had a higher hazard (adjusted HR, 4.3; 95% CI, 1.1–17.6) for poor outcome when 
compared with those who did not. Alcohol consumption during treatment was not 
independently associated with death (HR, 0.9; 95% CI, 0.2–3.1) or default from treatment 
(HR, 0.8; 95% CI, 0.2–3.3).
Of note, when testing for potential confounding, we discovered that persons who consumed 
alcohol during treatment were nearly seven times more likely to miss more than seven 
intensive-phase doses than those who did not consume alcohol during treatment (relative 
risk, 6.6; 95% CI, 3.2–13.6). A closer examination of the mean number of doses missed 
during treatment stratified by outcome and alcohol consumption are presented in Table 2. 
Persons with unsuccessful treatment outcomes, on average, missed seven more intensive-
phase doses (95% CI, 3.8–9.3) than those with successful outcomes (Table 2). Persons who 
consumed alcohol during treatment, on average, missed 18 more intensive-phase doses (95% 
CI, 13.2–21.8) than those who did not (Table 2).
Discussion
In this retrospective cohort study of patients treated for multidrug-resistant tuberculosis in 
Kerala, we found that the majority (63%) of patients had a successful outcome. This success 
rate was higher than reported at the national (47%) and global levels (53%) (2, 3), but 
similar to recent metaanalyses or large cohort studies conducted elsewhere (14–16).
Despite a high prevalence of diabetes mellitus (33.5%), more than three tuberculosis 
treatment episodes (36.6%), low body mass index at diagnosis (47.5%), and pulmonary 
cavities at the time of diagnosis (52.5%), these factors, although previously found to be 
associated with unsuccessful outcomes in other studies (14–16), were not associated with 
outcome in our cohort. Consuming alcohol during treatment was the only factor 
independently associated with unsuccessful outcome.
Kerala has the highest per capita rate of alcohol consumption in India, with more than 8 L 
per person per annum—a rate nearly three times higher than the national rate (17, 18). Over 
the past 4 years, alcohol sales have doubled and contribute to major revenues in Kerala’s 
state annual budget (19). These statistics are especially concerning considering that alcohol 
use during treatment of multidrug-resistant tuberculosis appears to be the most important 
risk factor for unsuccessful treatment outcomes in Kerala. Alcohol abuse has long been 
associated with unsuccessful treatment compliance and clinical outcomes for a variety of 
illnesses, including tuberculosis (20–24). Numerous studies have demonstrated that persons 
who abuse alcohol were more likely to default from tuberculosis treatment (21–24).
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The relationship between alcohol consumption and treatment outcomes is complex. First, 
from a treatment adherence perspective, treatment interruptions are associated with an 
increased risk for treatment default, failure, or death (22, 25). Moreover, several studies 
have reported that persons who drink alcohol in excess are more likely to have treatment 
interruptions (25, 26). In Kerala, those who drank alcohol during treatment missed more 
doses during both intensive-phase and continuation-phase of tuberculosis treatment than 
those who did not. Therefore, missed doses probably are responsible for the majority of 
unsuccessful outcomes. However, some patients consumed alcohol while they were adherent 
and still suffered unsuccessful treatment outcome. Alcohol consumption detracts from 
general health and may impair immune responses against M. tuberculosis, which thus may 
lead to treatment failure or delayed response to treatment (27). In immunocompetent 
persons, more than 90% of inhaled M. tuberculosis bacteria are eradicated from the body by 
alveolar macrophages (28). Several studies have demonstrated that alcohol improves in vitro 
intracellular survival of mycobacteria within human macrophages by suppressing 
mobilization, adherence, phagocytosis, and superoxide production (28, 29). Alcohol has 
been shown to decrease antigen-specific T-cell activation by disrupting the capacity to 
present mycobacterial antigens to lymphocytes (30). Moreover, chronic alcohol exposure 
may suppress cytokine production, which has an essential role in cellular communication, 
activation, proliferation, and migration, and in regulating inflammation and other healing 
mechanisms (31). Among patients who failed to convert on sputum culture, three of nine 
(33%) consumed alcohol during treatment, one of whom missed only two doses during the 
intensive phase (data not shown), suggesting failure may have been attributed to the effects 
of alcohol as opposed to effective treatment and adherence.
Despite the well-recognized implications of alcohol consumption on treatment adherence 
and outcome, few programs have been implemented that specialize in the simultaneous 
treatment of both tuberculosis and alcoholism. To our knowledge, only one program has 
been implemented that specifically focused on an integrative approach (32). This program in 
Tomsk, Russia, increased the proportion of favorable tuberculosis treatment outcomes 
among persons with a history of attempting to abstain from drinking alcohol by 18% (33). 
Although it is unclear if this approach would be effective in other communities, a recent 
study that assessed the feasibility of integrated alcoholism–tuberculosis treatment and care 
suggested the immediate need in India (34). It has been suggested that national tuberculosis 
programs, such as the Revised National Tuberculosis Control Program, could provide the 
infrastructure for an integrative approach where specialized alcoholism treatment services 
are almost nonexistent in the public sector (32). Moreover, given that alcohol abuse is a 
psychiatric disorder and that some patients experience other psychiatric drug-related adverse 
events during multidrug-resistant tuberculosis treatment, pretreatment clinical examinations 
might benefit from the inclusion of psychological assessments to screen for alcohol abuse 
disorders and other psychological conditions. However, the decision to invest in an 
integrative program should be approached with caution, especially among multidrug-
resistant tuberculosis treatment programs—balancing current resources for effective 
tuberculosis program delivery offset by the additional training and other requirements that 
may be needed to take on new and potentially demanding responsibilities.
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Notably in this cohort, all patients received the same standardized multidrug-resistant 
tuberculosis regimen, without regard for drug susceptibility test results. Individualized 
treatment regimens tailored to all drug susceptibility test results are recommended but 
require substantial clinical management that may be resource intensive (35, 36).
This study has several limitations. First, our findings were based on data that were 
abstracted from routinely collected records and reports designed to capture clinical 
encounters and surveillance information. Because of the retrospective nature of the study 
and because all of the source records and reports were not designed for study purposes, 
some information may be incomplete or contain errors. Second, follow-up time was limited 
to the completion of treatment. Although this time frame is sufficient for documenting 
surveillance-based treatment outcomes, it may not be sufficient to assess long-term clinical 
outcomes. It is possible that some of the patients may have recurrent episodes in the future. 
Third, our cohort was limited to patients treated in one state in India during one time period, 
and our findings should be explored in other settings if they are to be generalized. Fourth, it 
is possible that some important factors previously associated with unsuccessful treatment 
outcomes (e.g., HIV, diabetes mellitus, delayed treatment initiation, previous treatment 
episodes, and malnutrition) may become statistically significant with a larger cohort that is 
followed for a longer period of time. Fifth, we did not qualify the amount of alcohol 
consumed. However, because each patient was counseled to abstain from consuming alcohol 
during treatment to avoid potential harmful hepatotoxic effects of concomitant alcohol use 
with antituberculosis drugs, we believe any alcohol consumption may be an indicator for 
more serious alcohol-related behavioral disorders or at the very least a hazardous risk factor. 
Finally, second-line drug susceptibilities were not considered when determining treatment 
regimens; it is possible that some patients had unsuccessful outcomes because of ineffective 
treatment owing to resistance to one or more second-line antituberculosis drugs.
Conclusions
Kerala has the highest per capita rates of alcohol consumption in India. Among patients with 
multidrug-resistant tuberculosis in Kerala, consumption of alcohol during treatment was 
associated with poor treatment outcomes. The Revised National Tuberculosis Control 
Program should consider implementing pretreatment clinical examinations that include 
psychological assessments to screen for alcohol abuse disorders and other psychological 
conditions and develop an integrative approach to managing drug-resistant tuberculosis and 
alcohol use disorders simultaneously in this state.
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Figure 1. 
Kaplan-Meier survival curve of time survival versus alcohol usage during multidrug-
resistant tuberculosis (MDR-TB) treatment in 179 patients in Kerala, India. The P value 
reflects the results of the log-rank test of the equality of the two survival curves. Survival is 
measured in months after starting MDR-TB treatment.
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Table 2
Mean number of antituberculosis drug doses missed during intensive phase and continuation phase of 
treatment of multidrug-resistant tuberculosis patients in Kerala, India, 2009–2010
N = 179 Mean No. of Missed Doses (SD) Mean Difference* (95% CI) P Value
Intensive phase
 Unsuccessful treatment outcome†
  Yes   67   7.2 (14.2) 6.6 (3.8 to 9.3) <0.0001
  No 112 0.6 (3.3)
 Alcohol consumption during treatment
  Yes   16 19.1 (22.0)  17.5 (13.2 to 21.8) <0.0001
  No 159 1.6 (5.4)  
Continuation phase
 Unsuccessful treatment outcome†
  Yes   67 7.6 (22.1) 4.2 (−0.7 to 9.1) 0.09
  No 112 3.4 (11.0)
 Alcohol consumption during treatment
  Yes   16 12.5 (28.5)  8.1 (−0.3 to 16.5) 0.06
  No 159 4.4 (14.5)
Boldface indicates statistically significant at α = 0.05.
*
Equal variances assumed.
†
Includes treatment failure, default, death, adverse drug reactions, and development of extensively drug-resistant tuberculosis treatment.
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